HC Wainwright Reiterates Buy Rating on Cytokinetics, Keeps $140 Target
HC Wainwright reiterated its Buy rating on Cytokinetics and maintained a $140 price target. The target implies 126.0% upside from the Oct. 16 close of $61.95.
HC Wainwright reiterated its Buy rating on Cytokinetics and maintained a $140 price target. The target implies 126.0% upside from the Oct. 16 close of $61.95.